. All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise, references in this report to AN2, we, our, the Company or the Registrant refer to AN2 Therapeutics. Overview We are a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and o...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-17 | 2025-12-31 | 0001193125-26-110693 | EDGAR | 79K words |
| 2025-03-25 | 2024-12-31 | 0000950170-25-044366 | EDGAR | — |
| 2024-03-29 | 2023-12-31 | 0000950170-24-038681 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010627 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277673 | EDGAR | 60K words |
| 2025-08-12 | 2025-06-30 | 0000950170-25-107301 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070358 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126282 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096243 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059556 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062081 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041378 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021291 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023901 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016900 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-008999 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001193125-26-117765 | EDGAR | 1K words |
| 2026-03-17 | 0001193125-26-110681 | EDGAR | — |
| 2026-03-10 | 0001193125-26-099169 | EDGAR | — |
| 2026-01-29 | 0001193125-26-029540 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277662 | EDGAR | — |
| 2025-08-12 | 0000950170-25-107278 | EDGAR | — |
| 2025-06-20 | 0001193125-25-143187 | EDGAR | — |
| 2025-06-11 | 0001193125-25-138796 | EDGAR | — |
| 2025-05-27 | 0001193125-25-127595 | EDGAR | — |
| 2025-05-13 | 0000950170-25-070305 | EDGAR | — |
60 total filings indexed. 34 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001880438 |
| Ticker | ANTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.an2therapeutics.com |
| Listed | 2022-03-25 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ANTX (~200 tokens, structured JSON with cryptographic provenance)